2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

פוסט זה זמין גם ב: עברית

José A JoglarMina K ChungAnastasia L Armbruster 1Emelia J BenjaminJanice Y ChyouEdmond M CroninAnita Deswal 1Lee L EckhardtZachary D GoldbergerRakesh GopinathannairBulent GorenekPaul L Hess 2Mark HlatkyGail Hogan 3Chinwe IbehJulia H IndikKazuhiko Kido 4Fred KusumotoMark S LinkKathleen T Linta 3Gregory M MarcusPatrick M McCarthyNimesh PatelKristen K PattonMarco V PerezJonathan P PicciniAndrea M Russo 5Prashanthan SandersMegan M StreurKevin L ThomasSabrina Times 6James E TisdaleAnne Marie Valente 7David R Van Wagoner

Abstract             

Aim: The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.

Methods: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

Structure: Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.

Keywords: AHA Scientific Statements; acute coronary syndrome; alcohol; anticoagulants; anticoagulation agents; antiplatelet agents; apixaban; atrial fibrillation; atrial flutter; cardioversion; catheter ablation; coronary artery disease; coronary heart disease; dabigatran; edoxaban; exercise; heart failure; hypertension; idarucizumab; left atrial appendage occlusion; myocardial infarction; obesity; percutaneous coronary intervention; pulmonary vein isolation; risk factors; rivaroxaban; sleep apnea; stents; stroke; surgical ablation; thromboembolism; warfarin.

השארת תגובה

חייבים להתחבר כדי להגיב.

גלילה לראש העמוד
Open chat
Scan the code
האיגוד הישראלי לרפואהה דחופה
שלום, קשר ישיר עם ההנהלת האתר איך אפשר לעזור?

Direct contact with the website management
How can we help?
דילוג לתוכן